Medicine and Dentistry
Cytoreductive Surgery
91%
Hyperthermic Intraperitoneal Chemotherapy
87%
Malignant Neoplasm
74%
Metastatic Colorectal Cancer
73%
Adjuvant Chemotherapy
67%
Overall Survival
65%
Colorectal Carcinoma
59%
Metastatic Carcinoma
52%
Immunotherapy
45%
Diseases
40%
Neoplasm
39%
Lung Metastasis
38%
Peritoneum Metastasis
36%
Predictive Marker
35%
Elderly Patient
35%
Stomach Adenocarcinoma
35%
Colon Carcinoma
35%
Pancreas Cancer
35%
Intraperitoneal Chemotherapy
34%
Peritoneum Cancer
31%
Hazard Ratio
30%
Receptor Binding
30%
Clinical Trial
27%
Antibody Response
26%
Pooled Analysis
26%
Breast Cancer
26%
Oxaliplatin
24%
Disease Free Survival
24%
Tumor Differentiation
23%
Bevacizumab
23%
Radiosurgery
23%
Celiac Plexus
23%
Solid Malignant Neoplasm
22%
Adjuvant Therapy
22%
High Risk Population
21%
Severe Acute Respiratory Syndrome Coronavirus 2
20%
DNA Mismatch Repair
19%
Lung
18%
Preoperative Chemotherapy
18%
Progression Free Survival
18%
Cancer
18%
Neutralizing Antibody
17%
Liver Metastasis
17%
Microsatellite Instability
17%
Prospective Study
16%
Monotherapy
15%
Arm
15%
Retrospective Cohort Study
15%
Adenocarcinoma
14%
Immune Checkpoint Inhibitor
14%
Keyphrases
Metastatic Colorectal Cancer (mCRC)
100%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
99%
Cytoreductive Surgery
89%
Adjuvant Chemotherapy
70%
Overall Survival
52%
Predictive Marker
47%
Confidence Interval
40%
Colorectal Cancer
37%
Pancreatic Cancer
37%
Colorectal Metastases
35%
Elderly Patients
35%
Breast Cancer Susceptibility Gene 1 (BRCA1)
35%
Radiosurgery
35%
Patients with Cancer
31%
Pathological Stage
29%
Oncological Outcomes
29%
Cancer Patients
28%
Secondary Cytoreductive Surgery
27%
Prognostic Marker
27%
Lung Metastasis
27%
Liver Metastasis
26%
Pooled Analysis
26%
Locally Advanced
26%
Peritoneal Cancer Index
25%
Solid Tumors
23%
T1N0
23%
Tumor Differentiation
23%
Bevacizumab
23%
BNT162b2 Vaccine
23%
Stage III Colon Cancer
23%
Nested Case-control Study
23%
Advanced Gastric Adenocarcinoma
23%
Long-term Survival
23%
Colorectal Carcinoma
23%
Celiac Plexus
23%
Hazard Ratio
22%
Tumor
22%
Adjuvant Therapy
21%
Microsatellite Instability-high (MSI-H)
21%
Young Patients
21%
Receptor-binding Domain
19%
Mismatch Repair
19%
Vaccine Dose
18%
Lung
18%
National Cancer Database
18%
Disease-free Survival
18%
Oxaliplatin
17%
Chemotherapy
17%
Seropositivity
17%
Antibody Response
17%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
83%
Chemotherapy
81%
Colorectal Carcinoma
76%
Neoplasm
62%
Overall Survival
51%
Metastatic Colorectal Cancer
47%
Colon Carcinoma
47%
Diseases
44%
Immunotherapy
41%
Pancreas Cancer
39%
Clinical Trial
31%
Lung Metastasis
27%
Pancreas Adenocarcinoma
24%
Case-Control Study
23%
Protein P53
23%
Bevacizumab
23%
Long Term Survival
23%
Liver Metastasis
20%
Carcinoembryonic Antigen
20%
Monotherapy
17%
Progression Free Survival
16%
Abdominal Cancer
15%
Ipilimumab
14%
Melanoma
14%
Receptor
14%
Prospective Study
14%
Oxaliplatin
13%
Mouse Model
13%
Breast Cancer
13%
Fluorine 18
11%
Beta Adrenergic Receptor Blocking Agent
11%
Non Small Cell Lung Cancer
11%
Homeodomain Interacting Protein Kinase 2
11%
Rectum Carcinoma
11%
Blood Clotting Factor 12
11%
Early Growth Response Factor 1
11%
Aromatase
11%
Fluorodeoxyglucose
11%
Synergistic Therapy
11%
Olaparib
11%
Nivolumab
11%
Hepcidin
11%
COVID-19 Vaccine
11%
Prostaglandin E2
11%
Rectum Cancer
11%
Stomach Adenocarcinoma
11%
Iron
11%
Lewis Carcinoma
11%
Synapsin I
11%
Posttraumatic Stress Disorder
11%